Orlistat-Akrikhin is used orally with each main meal (during meals, immediately before meals, or no later than 1 hour after meals). The capsules should be taken with water. For long-term therapy, obese patients (BMI ≥ 30 kg / m2) or overweight (BMI ≥ 28 kg / m2) with obesity-related risk factors, aged 12 years and older, on a moderately restricted low-calorie diet should take Orlistat-Akrikhin at a dose of 120 mg of orlistat (1 capsule) 3 times a day. When prescribing the drug to adult patients with type 2 diabetes mellitus with obesity or overweight with combined intake of hypoglycemic agents and / or following a moderately limited hypocaloric diet, it is recommended to take 120 mg of orlistat (1 capsule) 3 times a day. It is allowed to skip the next intake of the capsule in the event that the food does not contain fat or the meal has been skipped. During the period of therapy, it is required to adhere to a balanced, moderately limited hypocaloric diet containing no more than 30% of calories in the form of fats; it is also recommended to include fruits and vegetables in the daily diet. The total amount of carbohydrates, fats and proteins consumed per day must be divided into three main doses. When using orlistat in doses exceeding 3 capsules per day, there was no increase in the therapeutic effect. The study of the safety and effectiveness of taking Orlistat-Akrikhin in patients with functional impairment of the liver and / or kidneys has not been conducted.

Absolute: cholestasis; chronic malabsorption syndrome; age up to 12 years; pregnancy and lactation; hypersensitivity to any of the constituents of Orlistat-Akrikhin. With extreme caution, the drug should be treated with concomitant administration of cyclosporine, warfarin or other oral anticoagulants.

The undesirable effects caused by taking orlistat appeared in most cases from the gastrointestinal tract and were associated with the pharmacological action of a drug that blocks the absorption of food fats. During the period of taking Orlistat-Akrikhin, the following disorders may occur: metabolism and nutritional disorders: very often - hypoglycemia; infectious and parasitic lesions: very often - influenza; nervous system: very often - headache; mental disorders: often - anxiety; respiratory system, chest and mediastinal organs: very often - upper respiratory tract infections; often - lower respiratory tract infections; genitals and mammary gland: often - irregular menstruation; kidneys and urinary tract: often - urinary tract infections; Gastrointestinal tract: very often - oily discharge from the rectum, abdominal discomfort / pain, gas with a certain amount of discharge, flatulence, loose stools, urge to defecate, increased frequency of bowel movements, steatorrhea; often - discomfort / pain in the rectum, fecal incontinence, soft stools, bloating, tooth damage, gum disease; general disorders: often - weakness. The nature and frequency of side effects in patients with type 2 diabetes were similar to those in patients without diabetes, overweight and obese. During treatment, the incidence of adverse reactions from the gastrointestinal tract increased with an increase in the amount of fat in the food consumed. It is possible to eliminate or reduce the severity of these disorders by following a diet low in fat. In most cases, the above effects were transient and mild, their appearance was noted mainly in the first 3 months of therapy and, as a rule, no more than one episode. Against the background of long-term use of Orlistat-Akrikhin, the incidence of these phenomena decreased.

amiodarone - there may be a decrease in the level of this substance in the blood plasma, clinical observation and monitoring of ECG indicators should be carried out; antiepileptic drugs - the absorption of these drugs decreases, which can cause the development of seizures; cyclosporine - the level of its content in the blood plasma decreases, which may lead to a weakening of the immunosuppressive efficacy of the drug; this combination is not recommended, if necessary, its implementation requires frequent monitoring of the plasma concentration of cyclosporine, both with concomitant administration of orlistat, and after its completion; warfarin and other anticoagulants - a decrease in the concentration of prothrombin and an increase in the international normalized ratio (INR) is possible, which can lead to a change in hemostatic parameters; with this combination, it is necessary to monitor INR indicators; fat-soluble vitamins A, D, E, K and beta-carotene - absorption of these substances is weakened; with combined use, they must be taken before bedtime or no earlier than 2 hours after taking orlistat; acarbose - it is recommended to avoid combined use due to the lack of pharmacokinetic interaction studies; levothyroxine sodium - hypothyroidism may develop and / or a decrease in its control due to a decrease in the absorption of levothyroxine sodium and / or inorganic iodine; oral contraceptives - the risk of a decrease in the contraceptive effect is aggravated, which in some cases increases the likelihood of an unplanned pregnancy; you should resort to additional methods of contraception, including in the event of severe diarrhea; antiretroviral drugs for the treatment of human immunodeficiency virus (HIV), antipsychotics (including lithium preparations), antidepressants, benzodiazepines - the therapeutic effect of these drugs may be weakened; starting therapy with orlistat in such patients should be after a careful assessment of the expected benefit from this treatment and the possible risk; fibrates, atorvastatin, digoxin, amitriptyline, biguanides, losartan, pravastatin, fluoxetine, phentermine, sibutramine, nifedipine, phenytoin, ethanol - no interaction with these drugs was observed.

Cases of drug overdose are not described. When taking single (800 mg) and multiple doses (for 15 days up to 400 mg three times a day) of orlistat in persons with normal body weight / obesity, undesirable effects did not occur. When orlistat was taken by obese patients for 6 months at a dose of 240 mg three times a day, there was no increase in the incidence of adverse reactions. In case of a significant overdose of Orlistat-Akrikhin, the patient should be observed for 24 hours. According to the data of clinical and preclinical studies, systemic effects associated with the lipase-inhibiting properties of orlistat should be quickly reversible.